Lawrence Van Helleputte

Lawrence holds a PhD in Neurobiology from the KU Leuven/VIB Center for Brain & Disease Research. In the Ludo Van Den Bosch lab, he focused on the potential of HDAC6 inhibitors as a therapy for CIPN and CMT, research that later became the foundation of Augustine Therapeutics. Next, he spent a couple of years in biotech, advancing preclinical stage assets to FIH, before making the transition to Venture capital. He currently serves as Associate at Droia Ventures, a Belgium based VC with extensive expertise in genetic diseases; backing several companies in the space, including Actio Biosciences and Alesta Therapeutics. Within Alesta, he aims to bring wearable technologies and leverage data from NH studies to facilitate clinical development and bring new therapies to the patients.